RAPT Therapeutics
RAPT
Performance
About RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics that target key drivers of the immune system to treat inflammatory and immunologic diseases. The company emphasizes cutting-edge science to advance treatments that can transform outcomes for patients with inflammatory and immunologic conditions across their research and development efforts. Based in the United States, RAPT communicates a mission to improve and empower lives through precision therapies that address immune system pathways.
Recent News
First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
GSK Reaches $2.2bn Deal to Buy Food Allergy Biotech RAPT
GSK Delivers in New CEO Miels' First Financial Update
Eight Allergy Companies to Watch in 2026
TAC to the Future. Plus: GSK’s Rapt Deal, Codifying MFN — a BioCentury Podcast